Key result
Rare MYH6 variants affect >10% of HLHS patients and are linked to decreased transplant-free survival.
Why the study?
The multifactorial etiology of hypoplastic left heart syndrome makes it difficult to interpret the clinical significance of genetic variants.
Answers are grounded in this paper and cite their sources.
MYH6 variants are present in over 10% of HLHS patients and are linked to decreased transplant-free survival, highlighting the importance of genetic testing in this population.
Hypoplastic left heart syndrome (HLHS) is a severe congenital heart disease (CHD) with complex genetic inheritance. HLHS segregates with other left ventricular outflow tract (LVOT) malformations in families, and can present as either an isolated phenotype or as a feature of a larger genetic disorder. The multifactorial etiology of HLHS makes it difficult to interpret the clinical significance of genetic variants. Specific genes have been implicated in HLHS, including rare, predicted damaging MYH6 variants that are present in >10% of HLHS patients, and which have been shown to be associated with decreased transplant-free survival in our previous studies. MYH6 (α-myosin heavy chain, α-MHC) variants have been reported in HLHS and numerous other CHDs, including LVOT malformations, and may provide a genetic link to these disorders. In this paper, we outline the MYH6 variants that have been identified, discuss how bioinformatic and functional studies can inform clinical decision making, and highlight the importance of genetic testing in HLHS.
No takes yet. Share an insight, caveat, or question.
Anfinson et al. (2022) conducted a review in Hypoplastic left heart syndrome (HLHS). Rare, predicted damaging MYH6 variants are present in >10% of hypoplastic left heart syndrome patients and are associated with decreased transplant-free survival.
Synapse has enriched 10 related papers. Consider them for comparative context: